BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang H, McCarty N. CRISPR-Cas9 technology and its application in haematological disorders. Br J Haematol 2016;175:208-25. [PMID: 27619566 DOI: 10.1111/bjh.14297] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Vuelta E, Ordoñez JL, Sanz DJ, Ballesteros S, Hernández-Rivas JM, Méndez-Sánchez L, Sánchez-Martín M, García-Tuñón I. CRISPR/Cas9-Directed Gene Trap Constitutes a Selection System for Corrected BCR/ABL Leukemic Cells in CML. Int J Mol Sci 2022;23:6386. [PMID: 35742831 DOI: 10.3390/ijms23126386] [Reference Citation Analysis]
2 Selvaraj D, Dawar R, Sivakumar PK, Devi A. Clustered regularly interspaced short palindromic repeats, a glimpse - impacts in molecular biology, trends and highlights. Horm Mol Biol Clin Investig 2021. [PMID: 34881529 DOI: 10.1515/hmbci-2021-0062] [Reference Citation Analysis]
3 Khalil AM. The genome editing revolution: review. J Genet Eng Biotechnol 2020;18:68. [PMID: 33123803 DOI: 10.1186/s43141-020-00078-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 20.0] [Reference Citation Analysis]
4 Amjad F, Fatima T, Fayyaz T, Khan MA, Qadeer MI. Novel genetic therapeutic approaches for modulating the severity of β-thalassemia (Review). Biomed Rep 2020;13:48. [PMID: 32953110 DOI: 10.3892/br.2020.1355] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
5 Liu W, Yang C, Liu Y, Jiang G. CRISPR/Cas9 System and its Research Progress in Gene Therapy. Anticancer Agents Med Chem 2019;19:1912-9. [PMID: 31633477 DOI: 10.2174/1871520619666191014103711] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Das J, Bhatia P, Singh A. CRISP Points on Establishing CRISPR-Cas9 In Vitro Culture Experiments in a Resource Constraint Haematology Oncology Research Lab. Indian J Hematol Blood Transfus 2019;35:208-14. [PMID: 30988554 DOI: 10.1007/s12288-018-1008-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Porter SN, Levine RM, Pruett-Miller SM. A Practical Guide to Genome Editing Using Targeted Nuclease Technologies. Compr Physiol 2019;9:665-714. [PMID: 30873595 DOI: 10.1002/cphy.c180022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Rodríguez-Rodríguez DR, Ramírez-Solís R, Garza-Elizondo MA, Garza-Rodríguez ML, Barrera-Saldaña HA. Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review). Int J Mol Med 2019;43:1559-74. [PMID: 30816503 DOI: 10.3892/ijmm.2019.4112] [Cited by in Crossref: 21] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
9 Babačić H, Mehta A, Merkel O, Schoser B. CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review. PLoS One 2019;14:e0212198. [PMID: 30794581 DOI: 10.1371/journal.pone.0212198] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
10 Foss DV, Hochstrasser ML, Wilson RC. Clinical applications of CRISPR-based genome editing and diagnostics. Transfusion 2019;59:1389-99. [PMID: 30600536 DOI: 10.1111/trf.15126] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
11 Conboy I, Murthy N, Etienne J, Robinson Z. Making gene editing a therapeutic reality. F1000Res 2018;7:F1000 Faculty Rev-1970. [PMID: 30613384 DOI: 10.12688/f1000research.16106.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
12 Antony JS, Haque AA, Lamsfus-calle A, Daniel-moreno A, Mezger M, Kormann MS. CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases. Adv Cell Gene Ther 2018;1:e10. [DOI: 10.1002/acg2.10] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
13 Khan S, Mahmood MS, Rahman SU, Zafar H, Habibullah S, Khan Z, Ahmad A. CRISPR/Cas9: the Jedi against the dark empire of diseases. J Biomed Sci 2018;25:29. [PMID: 29592810 DOI: 10.1186/s12929-018-0425-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
14 García-Tuñón I, Hernández-Sánchez M, Ordoñez JL, Alonso-Pérez V, Álamo-Quijada M, Benito R, Guerrero C, Hernández-Rivas JM, Sánchez-Martín M. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia. Oncotarget 2017;8:26027-40. [PMID: 28212528 DOI: 10.18632/oncotarget.15215] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
15 Hwang Y, Broxmeyer HE, Lee MR. Generating autologous hematopoietic cells from human-induced pluripotent stem cells through ectopic expression of transcription factors: . Current Opinion in Hematology 2017;24:283-8. [DOI: 10.1097/moh.0000000000000343] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zhang H, McCarty N. CRISPR Editing in Biological and Biomedical Investigation. J Cell Biochem 2017;118:4152-62. [PMID: 28467679 DOI: 10.1002/jcb.26111] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]